Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2009

01-05-2009 | Original Article

Serum Level of Adiponectin Correlated with Gender and Genotype in Patients with Chronic Hepatitis C

Authors: Qing-Hua Meng, Zhong-Hui Duan, Zun-Hui Lin, Hong-Wei Yu, Juan Li, Ya Liu

Published in: Digestive Diseases and Sciences | Issue 5/2009

Login to get access

Abstract

Adiponectin is well recognized as plasma physiologically active polypeptide hormone exclusively derived from human and animal mature adipocytes, with vigorous property in antidiabetic, antiobesity, antiatherogenic, and anti-inflammatory processes. In this study, we investigated the correlation between serum adiponectin level and clinical and pathological parameters in patients with chronic hepatitis C (CHC). The study included 127 patients with CHC and 42 healthy volunteers as controls whose laboratory parameters and serum adiponectin and tumor necrosis factor-α (TNF-α) were assessed using enzyme-linked immunosorbent assay (ELISA). We demonstrated that a lower serum adiponectin level was associated with male gender, higher γ-glutamyltransferase (γ-GGT), higher albumin, higher TNF-α, and steatosis grade. The higher level of serum adiponectin in patients with genotype 2a was demonstrated when compared with that in the patients with genotype 1b. Furthermore, of great interest, results suggested that the significant differences regarding viral genotype seemed to occur only in male patients with CHC but not in female patients. In conclusion, serum adiponectin was associated with gender, genotype, liver steatosis, and TNF-α in a Chinese population with CHC.
Literature
1.
go back to reference Semple RK, Halberg NH, Burling K, et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes. 2007;56:1712–1717. doi:10.2337/db06-1665.PubMedCrossRef Semple RK, Halberg NH, Burling K, et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes. 2007;56:1712–1717. doi:10.​2337/​db06-1665.PubMedCrossRef
11.
go back to reference Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006;48:1369–1377. doi:10.1016/j.jacc.2006.06.053.PubMedCrossRef Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006;48:1369–1377. doi:10.​1016/​j.​jacc.​2006.​06.​053.PubMedCrossRef
17.
go back to reference Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab. 2005;90:2240–2243. doi:10.1210/jc.2004-1266.PubMedCrossRef Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab. 2005;90:2240–2243. doi:10.​1210/​jc.​2004-1266.PubMedCrossRef
19.
21.
24.
25.
30.
37.
38.
go back to reference Chuang JH, Wang PW, Tai MH. An adipocentric view of liver fibrosis and cirrhosis. Chang Gung Med J. 2004;27:855–868.PubMed Chuang JH, Wang PW, Tai MH. An adipocentric view of liver fibrosis and cirrhosis. Chang Gung Med J. 2004;27:855–868.PubMed
39.
go back to reference Kara B, Gunesacar R, Doran F, Kara IO, Akkiz H. Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection. Adv Ther. 2007;24:972–982. doi:10.1007/BF02877701.PubMedCrossRef Kara B, Gunesacar R, Doran F, Kara IO, Akkiz H. Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection. Adv Ther. 2007;24:972–982. doi:10.​1007/​BF02877701.PubMedCrossRef
40.
go back to reference Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load : impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig. 2008;28:9–16. doi:10.2165/00044011-200828010-00002.PubMedCrossRef Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load : impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig. 2008;28:9–16. doi:10.​2165/​00044011-200828010-00002.PubMedCrossRef
41.
go back to reference Dal Pero F, Tang KH, Gerotto M, et al. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon-alpha 2a plus ribavirin. J Infect Dis. 2007;196:998–1005. doi:10.1086/521306.PubMedCrossRef Dal Pero F, Tang KH, Gerotto M, et al. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon-alpha 2a plus ribavirin. J Infect Dis. 2007;196:998–1005. doi:10.​1086/​521306.PubMedCrossRef
42.
go back to reference Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40 KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol. 2006;44:275–282. doi:10.1016/j.jhep.2005.09.015.PubMedCrossRef Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40 KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol. 2006;44:275–282. doi:10.​1016/​j.​jhep.​2005.​09.​015.PubMedCrossRef
43.
go back to reference Howell CD, Jeffers LS, Cassidy W, Reddy KR, Hu S, Lee JS. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J Viral Hepat. 2006;13:371–376. doi:10.1111/j.1365-2893.2005.00697.x.PubMedCrossRef Howell CD, Jeffers LS, Cassidy W, Reddy KR, Hu S, Lee JS. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J Viral Hepat. 2006;13:371–376. doi:10.​1111/​j.​1365-2893.​2005.​00697.​x.PubMedCrossRef
44.
go back to reference Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol. 2006;101:2629–2640.PubMed Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol. 2006;101:2629–2640.PubMed
Metadata
Title
Serum Level of Adiponectin Correlated with Gender and Genotype in Patients with Chronic Hepatitis C
Authors
Qing-Hua Meng
Zhong-Hui Duan
Zun-Hui Lin
Hong-Wei Yu
Juan Li
Ya Liu
Publication date
01-05-2009
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0455-z

Other articles of this Issue 5/2009

Digestive Diseases and Sciences 5/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.